CTOs on the Move

MediBeacon

www.medibeacon.com

 
MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.medibeacon.com
  • 1100 Corporate Square Drive Helix Center, Suite 175
    St. Louis, MO USA 63132
  • Phone: 314.269.5808

Executives

Name Title Contact Details

Funding

MediBeacon raised $22.4M on 08/27/2015

Similar Companies

Earlens

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was designed specifically to address the sound quality and speech understanding complaints that are common among hearing aid wearers and contribute to non-compliance. We make every Earlens device custom-fit for each patient`s unique anatomy and hearing needs, while offering modern features such as Bluetooth streaming.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.

Pennsylvania Occupational Therapy Association (POTA)

Pennsylvania Occupational Therapy Association (POTA) is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Devax

Devax is a Lake Forest, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Internal Medical Group

Internal Medical Group is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.